New Study Shows Severe Toxicity with High-Dose AAV9-Based Gene Therapy in Animal Models

Researchers have described severe, life-threatening toxicity in monkeys and piglets given high doses of gene therapy delivered using an adeno-associated virus (AAV9) vector capable of accessing spinal cord neurons. The liver and neuronal toxicity reported here are different than the immune-related toxicity described with other AAV vectors, as reported in an article published Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Human Gene Therapy website.

James M. Wilson, MD, and coauthors from the University of Pennsylvania Perelman School of Medicine, Philadelphia, evaluated the ability of an AAV9 variant (AAVhu68) to deliver a human gene to motor neurons in the spinal cords of young rhesus macaques and pigs. AAV9 is the same viral vector recently used successfully to deliver a therapeutic gene to infants with spinal muscular atrophy (SMA). High-dose intravenous gene therapy administration led to severe toxicity affecting the liver and motor neurons, with symptoms appearing within 5 days of treatment. The researchers reported their findings in the article titled “Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an AAV Vector Expressing Human SMN.”

Human Gene Therapy Editor-in-Chief Terence R. Flotte and Editor of Human Gene Therapy Methods Hildegard Büning urged the gene therapy community to interpret and respond to these findings “in a balanced and responsible fashion,” neither ignoring them nor over-reacting, in their Editorial entitled “Severe Toxicity in Non-Human Primates and Piglets with Systemic High-Dose Administration of AAV9-Like Vectors: Putting Patients First.” The editors point out the important limitations of the current study and suggest “that the one and only guiding principle in critical moments like this should be the welfare of patients with the diseases being treated with these therapies.”

“We advocate for full transparency with all relevant safety data from all laboratories, whether within academia, industry and government. While not all sources of vector are of equivalent quality and purity, the true properties of possible AAV9(-like) vector toxicities will inevitably be best illuminated by multiple different studies being performed by multiple independent groups. This is not a time to protect proprietary interests or academic rivalries. We assert this not out of naïveté, but rather based on our conviction that if the gene therapy research community makes patient welfare as the sole priority, it will ultimately be beneficial to us all,” says Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School.